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ABSTRACT 
Background Context: The clinical application of recombinant bone morphogenetic protein in 
spinal surgery has been shown to be safe and effective. However, its use in minimally 
invasive spine surgery has been limited to anterior interbody fusion procedures. To date, no 
study has evaluated the feasibility of percutaneous posterolateral fusion in the spine utilizing 
recombinant bone morphogenetic protein-2 (rhBMP-2). Purpose: To evaluate the feasibility 
of percutaneous posterolateral fusion in the spine utilizing rhBMP-2. Study Design: Animal 
study. Methods: This is an animal research model involving 32 New Zealand white rabbits 
stratified into 4 study groups: control, autogenous iliac crest bone graft (ICBG), 
demineralized bone matrix (DBM), and rhBMP-2 groups, with 8 study subjects per group. 
The rhBMP-2 group was subdivided into the open technique (right side) and the percutaneous 
technique groups (left side). Fusion was graded at 6 weeks and 3 months after plain 
radiography, computed tomography, and clinical assessment with the following grading 
system: grade A, no bone formation; grade B, non-bridging bone formation; grade C, fusion; 
and grade D, fusion with ectopic bone formation. Results: No fusion was noted in the placebo 
and the DBM groups. However, in the DBM group, bone formation occurred in 37.5% of the 
subjects. The rhBMP-2 group had a higher fusion rate compared with the ICBG group at 6 
weeks and 3 months. The fusion rate for the ICBG, the rhBMP-2 (open), and the rhBMP-2 
(percutaneous) groups were 37.5%, 87.5%, and 50.0% at 6 weeks and 50.0%, 100.0%, and 
62.5% at 3 months, respectively. Ectopic bone formation occurred in 12.5% of the cases in 
the rhBMP-2 (percutaneous) group and in 25.0% of the cases in the rhBMP-2 (open) group. 
Conclusions: Usage of rhBMP-2 is feasible for percutaneous posterolateral fusion of the 
lumbar spine in this animal model. However, a more precise delivery system might improve 
the fusion rate when the percutaneous technique is used. A significant rate of ectopic bone 
formation occurred when rhBMP-2 was used. 
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